Skip to main content
. 2021 Feb 22;16(3):384–395. doi: 10.2215/CJN.15260920

Figure 1.

Figure 1.

For all kidney-related efficacy outcomes, the relative benefits of canagliflozin were consistent across all urine albumin-to-creatinine ratio (UACR) categories. For kidney-related adverse events, a greater relative risk reduction was observed in higher UACR categories. For all kidney-related outcomes, absolute benefits were greatest in individuals with higher levels of UACR. 95% CI, 95% confidence interval; HR, hazard ratio.